{"id":"allopurinol","rwe":[],"_fda":{"id":"ee55d296-fcb3-4442-bfe5-b740e6ca20f2","set_id":"005048dd-844f-468c-bf56-1a09727e3477","openfda":{"nui":["N0000175698","N0000000206"],"unii":["63CZ7GJN5I"],"route":["ORAL"],"rxcui":["197320"],"spl_id":["ee55d296-fcb3-4442-bfe5-b740e6ca20f2"],"brand_name":["Allopurinol"],"spl_set_id":["005048dd-844f-468c-bf56-1a09727e3477"],"package_ndc":["63629-2113-1"],"product_ndc":["63629-2113"],"generic_name":["ALLOPURINOL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ALLOPURINOL"],"pharm_class_epc":["Xanthine Oxidase Inhibitor [EPC]"],"pharm_class_moa":["Xanthine Oxidase Inhibitors [MoA]"],"manufacturer_name":["Bryant Ranch Prepack"],"application_number":["ANDA075798"],"original_packager_product_ndc":["0603-2116"]},"version":"103","pregnancy":["8.1 Pregnancy Risk Summary Based on findings in animals, allopurinol tablets may cause fetal harm when administered to a pregnant woman. Adverse developmental outcomes have been described in exposed animals (see Data). Allopurinol and its metabolite oxypurinol have been shown to cross the placenta following administration of maternal allopurinol. Available limited published data on allopurinol use in pregnant women do not demonstrate a clear pattern or increase in frequency of adverse developmental outcomes. Among approximately 50 pregnancies described in published literature, 2 infants with major congenital malformations have been reported with following maternal allopurinol exposure. Advise pregnant women of the potential risk to a fetus. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Experience with allopurinol tablets during human pregnancy has been limited partly because women of reproductive age rarely require treatment with allopurinol tablets. A case report published in 2011 described the outcome of a full-term pregnancy in a 35-year-old woman who had recurrent kidney stones since age 18 who took allopurinol throughout the pregnancy. The child had multiple complex birth defects and died at 8 days of life. A second report in 2013 provided data on 31 prospectively ascertained pregnancies involving mothers exposed to allopurinol for varying durations during the first trimester. The overall rate of major fetal malformations and spontaneous abortions was reported to be within the normal expected range; however, one child had severe malformations similar to those described in the cited earlier case report. Animal Data There was no evidence of fetotoxicity or teratogenicity in rats or rabbits treated during the period of organogenesis with oral allopurinol at doses up to 200 mg/kg/day and up to 100 mg/kg/day, respectively (about 2.4 times the human dose on a mg/m 2 basis). However, there is a published report in pregnant mice that single intraperitoneal doses of 50 mg/kg or 100 mg/kg (about 0.3 or 0.6 times the human dose on a mg/m 2 basis) of allopurinol on gestation days 10 or 13 produced significant increases in fetal deaths and teratogenic effects (cleft palate, harelip, and digital defects). It is uncertain whether these findings represented a fetal effect or an effect secondary to maternal toxicity."],"overdosage":["10 OVERDOSAGE In the management of overdosage there is no specific antidote for allopurinol tablets. Both allopurinol tablets and oxipurinol are dialyzable; however, the usefulness of hemodialysis or peritoneal dialysis in the management of an overdose of allopurinol tablets is unknown."],"references":["15 REFERENCES"],"description":["11 DESCRIPTION Allopurinol, USP is a xanthine oxidase inhibitor. It has the following structural formula: Allopurinol, USP is known chemically as 1, 5-dihydro-4 H -pyrazolo [3, 4- d ]pyrimidin-4-one and it has a molecular weight of 136.1 g/mol. Soluble in solutions of potassium and sodium hydroxides, very slightly soluble in water and in alcohol; practically insoluble in chloroform and in ether. It is a xanthine oxidase inhibitor which is administered orally. Each scored white round-shaped tablet contains 100 mg allopurinol and the inactive ingredients colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate. Each scored orange round-shaped tablet contains 300 mg allopurinol and the inactive ingredients colloidal silicon dioxide, FD&C Yellow No. 6 Lake, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate."],"how_supplied":["16 HOW SUPPLIED 300 mg Orange, round and biconvex tablets. The upper layer is bisected and debossed with “2084/V”. The lower layer is plain. They are supplied as follows: Bottles of 1000: 63629-2113-1 Store at 20°C to 25°C (USP Controlled Room Temperature) (68°F to 77°F) in a dry place. Dispense in a tight container as defined in the USP. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504"],"boxed_warning":["BOXED WARNING"],"geriatric_use":["8.5 Geriatric Use"],"pediatric_use":["8.4 Pediatric Use Hyperuricemia Associated with Cancer Therapy The safety and effectiveness of allopurinol for the management of pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels have been established in approximately 200 pediatric patients. The efficacy and safety profile observed in this patient population were similar to that observed in adults. Primary or Secondary Gout The safety and effectiveness of allopurinol tablets have not been established for the treatment of signs and symptoms of primary or secondary gout in pediatric patients. Recurrent Calcium Oxalate Calculi The safety and effectiveness of allopurinol tablets have not been established for the management of pediatric patients with recurrent calcium oxalate calculi. Inborn Errors of Metabolism The safety and effectiveness of allopurinol tablets have not been established in pediatric patients with rare inborn errors of purine metabolism."],"effective_time":"20240708","nursing_mothers":["8.3 Nursing Mothers"],"clinical_studies":["14 CLINICAL STUDIES"],"pharmacodynamics":["12.2 Pharmacodynamics Allopurinol tablets reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation in a dose dependent manner. The pharmacological action of allopurinol is generally believed to be mediated by its oxypurinol metabolite. Effect on Hypoxanthine and Xanthine Reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by allopurinol tablets and oxipurinol. This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis. As a result of xanthine oxidase inhibition, the serum concentration of hypoxanthine plus xanthine in patients receiving allopurinol tablets for treatment of hyperuricemia is usually in the range of 0.3 mg/dL to 0.4 mg/dL compared to a normal level of approximately 0.15 mg/dL. A maximum of 0.9 mg/dL of these oxypurines has been reported when the serum urate was lowered to less than 2 mg/dL by high doses of allopurinol tablets. These values are far below the saturation levels at which point their precipitation would be expected to occur (above 7 mg/dL). The increased xanthine and hypoxanthine in the urine in patients who were treated with oral allopurinol have not been accompanied by problems of nephrolithiasis; however, there are isolated case reports of xanthine crystalluria. Drug Interaction Studies Fluorouracil: Based on non-clinical data, allopurinol may decrease anti-tumor activity due to suppression of phosphorylation of 5-fluorouracil. Pegloticase : Concomitant use of allopurinol tablets and pegloticase may potentially blunt the rise of serum uric acid levels required for monitoring the safe use of pegloticase. Cytotoxic Agents : Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol tablets. Thiazide Diuretics : Reports that the concomitant administration of allopurinol and thiazide diuretics contributed to increased allopurinol toxicity were reviewed; however, a causal mechanism or cause-and-effect relationship was not found."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Allopurinol tablets are approximately 90% absorbed from the gastrointestinal tract. Peak plasma levels generally occur at 1.5 hours and 4.5 hours for allopurinol tablets and oxipurinol respectively. After a single oral dose of 300 mg allopurinol tablets, maximum plasma levels of about 3 mcg/mL of allopurinol tablets and 6.5 mcg/mL of oxipurinol are produced. Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively. Metabolism Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol (alloxanthine), which also is an inhibitor of xanthine oxidase. Excretion Allopurinol tablets and its primary active metabolite, oxipurinol, are eliminated by the kidneys. Approximately 20% of the ingested allopurinol tablets is excreted in the feces. Oxipurinol is primarily eliminated unchanged in urine by glomerular filtration and tubular reabsorption. Drug Interaction Studies Capecitabine: Concomitant use with allopurinol may decrease concentration of capecitabine’s active metabolites, which may decrease capecitabine efficacy. Cyclosporine: Concomitant use of allopurinol increases cyclosporine concentrations which may increase the risk of adverse reactions. Mercaptopurine or Azathioprine: Allopurinol inhibits xanthine oxidase mediated metabolism of mercaptopurine and azathioprine. Concomitant use of allopurinol increases the exposure of either mercaptopurine or azathioprine which may increase the risk of their adverse reactions including myelosuppression. Theophylline: Concomitant use of allopurinol doses greater than or equal to 600 mg/day may decrease the clearance of theophylline. Uricosuric Agents: Uricosuric agents increase the excretion of the active allopurinol metabolite oxypurinol. Concomitant use with uricosuric agents decreases oxypurinol exposure which may reduce the inhibition of xanthine oxidase by oxypurinol and increases the urinary excretion of uric acid. Warfarin: Allopurinol may inhibit the metabolism of warfarin, possibly enhancing its anticoagulant effect."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Skin Rash and Hypersensitivity [see Warnings and Precautions ( 5.1 )] Nephrotoxicity [see Warnings and Precautions ( 5.3 )] Hepatoxicity [see Warnings and Precautions ( 5.4 )] Myelosuppression [see Warnings and Precautions ( 5.5 )] Potential Effect on Driving and Use of Machinery [see Warnings and Precautions ( 5.6 )] The following adverse reactions associated with the use of allopurinol tablets were identified in literature, unpublished clinical trials or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most frequent adverse reaction to allopurinol tablets is skin rash. Most Common Adverse Reactions (≥ 1%) Gastrointestinal : Diarrhea, nausea, alkaline phosphatase increase, AST/ALT increase. Metabolic and Nutritional : Acute attacks of gout. Skin and Appendages : Rash, maculopapular rash. Less Common Adverse Reactions (< 1%) Body As a Whole : Ecchymosis, fever, headache, malaise. Cardiovascular : Necrotizing angiitis, vasculitis, pericarditis, peripheral vascular disease, thrombophlebitis, bradycardia, vasodilation. Gastrointestinal : Hepatic necrosis, granulomatous hepatitis, hepatomegaly, hyperbilirubinemia, cholestatic jaundice, vomiting, intermittent abdominal pain, gastritis, dyspepsia, hemorrhagic pancreatitis, gastrointestinal bleeding, stomatitis, salivary gland swelling, hyperlipidemia, tongue edema, anorexia. Hemic and Lymphatic: Thrombocytopenia, eosinophilia, leukocytosis, leukopenia, aplastic anemia, agranulocytosis, eosinophilic fibrohistiocytic lesion of bone marrow, pancytopenia, prothrombin decrease, anemia, hemolytic anemia, reticulocytosis, lymphadenopathy, lymphocytosis. Musculoskeletal: Myopathy, arthralgias, myalgia. Nervous: Peripheral neuropathy, neuritis, paresthesia, somnolence, optic neuritis, confusion, dizziness, vertigo, foot drop, decrease in libido, depression, amnesia, tinnitus, asthenia, insomnia. Respiratory: Epistaxis, bronchospasm, asthma, pharyngitis, rhinitis. Skin and Appendages : Erythema multiforme exudativum (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), hypersensitivity vasculitis, purpura, vesicular bullous dermatitis, exfoliative dermatitis, eczematoid dermatitis, pruritus, urticaria, alopecia, onycholysis, lichen planus, furunculosis, facial edema, sweating, skin edema. Special Senses : Taste loss/perversion, cataracts, macular retinitis, iritis, conjunctivitis, amblyopia. Urogenital: Renal failure, uremia, nephritis, impotence, primary hematuria, albuminuria. Endocrine: Infertility (male), hypercalcemia, gynecomastia (male). Most common adverse reactions (incidence > 1%) are nausea, diarrhea, and increase in liver function tests. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS Allopurinol tablets are contraindicated in patients with a history of hypersensitivity reaction to allopurinol or to any of the ingredients of allopurinol tablets. Known hypersensitivity to allopurinol or to any of the ingredients of allopurinol tablets."],"drug_interactions":["7 DRUG INTERACTIONS The following drugs may increase the risk of serious skin reactions: bendamustine, thiazide diuretics, ampicillin and amoxicillin. ( 7.1 ) Capecitabine: Avoid concomitant use. ( 7.2 ) Mercaptopurine or Azathioprine: Reduce mercaptopurine or azathioprine dose as recommended in the respective prescribing information. ( 7.2 ) Pegloticase: Discontinue and refrain from initiating treatment with allopurinol tablets. ( 7.2 ) See FPI for complete list of significant drug interactions. ( 7.2 ) 7.1 Drugs Known to Affect the Occurrence of Skin Rash and Hypersensitivity Concomitant use of the following drugs may increase the risk of skin rash, which may be severe: bendamustine, thiazide diuretics, ampicillin and amoxicillin. Renal impairment may further increase risk with concomitant use of thiazide diuretics [see Warnings and Precautions ( 5.1 , 5.2 ) and Clinical Pharmacology ( 12.2 )] . Monitor kidney function and reduce the dose of allopurinol tablets in patients with concomitant thiazide diuretic use and impaired renal function [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.1 )]. Discontinue allopurinol tablets at the first appearance of skin rash or other signs which may indicate a hypersensitivity reaction when use concomitantly with these drugs [see Warnings and Precautions ( 5.1 )] . 7.2 Drugs Known to Have Clinically Important Drug Interactions with Allopurinol Tablets Table 3: Interventions for Clinically Important Drug Interactions with Allopurinol Tablets Capecitabine Clinical Impact Concomitant use with allopurinol may decrease concentration of capecitabine’s active metabolites, which may decrease capecitabine efficacy. Intervention Avoid the use of allopurinol tablets during treatment with capecitabine. Chlorpropamide Clinical Impact Allopurinol tablets prolong the half-life of chlorpropamide as both compete for renal tubular excretion. In patients with renal insufficiency, the risk of hypoglycemia may be increased due to this mechanism. Intervention Monitor patients with renal insufficiency for hypoglycemia when administering chlorpropamide and allopurinol tablets concomitantly. Cyclosporine Clinical Impact Concomitant use of allopurinol increases cyclosporine concentrations, which may increase the risk of adverse reactions. Intervention Increase frequency of monitoring cyclosporine concentrations as reflected in its prescribing information and modify the dosage of cyclosporine as appropriate when used concomitantly with allopurinol tablets. Cyclophosphamide and Other Cytotoxic Agents Clinical Impact Concomitant use of allopurinol with cyclophosphamide and other cytotoxic agents (doxorubicin, bleomycin, procarbazine, mechloroethamine) increases bone marrow suppression among patients with neoplastic disease, except leukemia. Intervention Blood count monitoring and regular physician follow-up are recommended. Dicumarol Clinical Impact Allopurinol tablets prolong the half-life of the anticoagulant, dicumarol. The mechanism of this drug interaction has not been established but should be noted when allopurinol tablets are given to patients already on dicumarol therapy. Intervention Monitor prothrombin time. Adjust the dosage of dicumarol accordingly when allopurinol tablets are added to anticoagulant therapy. Fluorouracil Clinical Impact Based on non-clinical data, allopurinol may decrease anti-tumor activity due to suppression of phosphorylation of 5-fluorouracil. Intervention Concomitant administration with fluorouracil should be avoided. Mercaptopurine or Azathioprine Clinical Impact Allopurinol inhibits xanthine oxidase mediated metabolism of mercaptopurine and azathioprine. Concomitant use of allopurinol increases the exposure of either mercaptopurine or azathioprine which may increase the risk of their adverse reactions, including myelosuppression [see Warnings and Precautions 5.5 ]. Intervention In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 mg to 600 mg of allopurinol tablets per day will require a reduction in dose to approximately one third to one fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects. Pegloticase Clinical Impact Concomitant use of allopurinol tablets and pegloticase may potentially blunt the rise of serum uric acid levels and increase the risk of pegloticase related anaphylaxis in patients whose uric acid level increase to above 6 mg/dL. Intervention Discontinue and do not institute allopurinol tablets therapy during treatment with pegloticase. Theophylline Clinical Impact Concomitant use of allopurinol doses greater than or equal to 600 mg/day may decrease the clearance of theophylline. Intervention Monitor and adjust theophylline doses as reflected in the prescribing information. Uricosuric Drugs Clinical Impact Uricosuric agents increase the excretion of the active allopurinol metabolite oxypurinol. Concomitant use with uricosuric agents decreases oxypurinol exposure which may reduce the inhibition of xanthine oxidase by oxypurinol and increases the urinary excretion of uric acid. The net effect of such combined therapy may be useful in some patients in achieving minimum serum uric acid levels provided the total urinary uric acid load does not exceed the competence of the patient's kidney function. Intervention Monitor uric acid levels due to the increased chance of hypouricemic effects. Warfarin Clinical Impact Allopurinol may inhibit the metabolism of warfarin, possibly enhancing its anticoagulant effect. Intervention Monitor patients on concomitant therapy for excessive anticoagulation. Assess INR frequently and adjust warfarin dosage accordingly when allopurinol is added to warfarin therapy."],"labor_and_delivery":["8.2 Lactation Risk Summary Allopurinol and oxypurinol are present in human milk. Based on information from a single case report, allopurinol and its active metabolite, oxypurinol, were detected in the milk of a mother receiving 300 mg of allopurinol daily at 5 weeks postpartum. The estimated relative infant dose were 0.14 mg/kg and 0.2 mg/kg of allopurinol and between 7.2 mg/kg to 8 mg/kg of oxypurinol daily. There was no report of effects of allopurinol on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatments with allopurinol tablets and for one week after the last dose."],"mechanism_of_action":["12.1 Mechanism of Action Allopurinol tablets are a structural analogue of the natural purine base, hypoxanthine. Allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in humans. Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol (alloxanthine), which also is an inhibitor of xanthine oxidase."],"recent_major_changes":[""],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Allopurinol tablets are a structural analogue of the natural purine base, hypoxanthine. Allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in humans. Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol (alloxanthine), which also is an inhibitor of xanthine oxidase. 12.2 Pharmacodynamics Allopurinol tablets reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation in a dose dependent manner. The pharmacological action of allopurinol is generally believed to be mediated by its oxypurinol metabolite. Effect on Hypoxanthine and Xanthine Reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by allopurinol tablets and oxipurinol. This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis. As a result of xanthine oxidase inhibition, the serum concentration of hypoxanthine plus xanthine in patients receiving allopurinol tablets for treatment of hyperuricemia is usually in the range of 0.3 mg/dL to 0.4 mg/dL compared to a normal level of approximately 0.15 mg/dL. A maximum of 0.9 mg/dL of these oxypurines has been reported when the serum urate was lowered to less than 2 mg/dL by high doses of allopurinol tablets. These values are far below the saturation levels at which point their precipitation would be expected to occur (above 7 mg/dL). The increased xanthine and hypoxanthine in the urine in patients who were treated with oral allopurinol have not been accompanied by problems of nephrolithiasis; however, there are isolated case reports of xanthine crystalluria. Drug Interaction Studies Fluorouracil: Based on non-clinical data, allopurinol may decrease anti-tumor activity due to suppression of phosphorylation of 5-fluorouracil. Pegloticase : Concomitant use of allopurinol tablets and pegloticase may potentially blunt the rise of serum uric acid levels required for monitoring the safe use of pegloticase. Cytotoxic Agents : Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol tablets. Thiazide Diuretics : Reports that the concomitant administration of allopurinol and thiazide diuretics contributed to increased allopurinol toxicity were reviewed; however, a causal mechanism or cause-and-effect relationship was not found. 12.3 Pharmacokinetics Absorption Allopurinol tablets are approximately 90% absorbed from the gastrointestinal tract. Peak plasma levels generally occur at 1.5 hours and 4.5 hours for allopurinol tablets and oxipurinol respectively. After a single oral dose of 300 mg allopurinol tablets, maximum plasma levels of about 3 mcg/mL of allopurinol tablets and 6.5 mcg/mL of oxipurinol are produced. Elimination The half-life of allopurinol and oxipurinol are approximately 1 hour to 2 hours and 15 hours following oral dose of allopurinol tablets, respectively. Metabolism Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol (alloxanthine), which also is an inhibitor of xanthine oxidase. Excretion Allopurinol tablets and its primary active metabolite, oxipurinol, are eliminated by the kidneys. Approximately 20% of the ingested allopurinol tablets is excreted in the feces. Oxipurinol is primarily eliminated unchanged in urine by glomerular filtration and tubular reabsorption. Drug Interaction Studies Capecitabine: Concomitant use with allopurinol may decrease concentration of capecitabine’s active metabolites, which may decrease capecitabine efficacy. Cyclosporine: Concomitant use of allopurinol increases cyclosporine concentrations which may increase the risk of adverse reactions. Mercaptopurine or Azathioprine: Allopurinol inhibits xanthine oxidase mediated metabolism of mercaptopurine and azathioprine. Concomitant use of allopurinol increases the exposure of either mercaptopurine or azathioprine which may increase the risk of their adverse reactions including myelosuppression. Theophylline: Concomitant use of allopurinol doses greater than or equal to 600 mg/day may decrease the clearance of theophylline. Uricosuric Agents: Uricosuric agents increase the excretion of the active allopurinol metabolite oxypurinol. Concomitant use with uricosuric agents decreases oxypurinol exposure which may reduce the inhibition of xanthine oxidase by oxypurinol and increases the urinary excretion of uric acid. Warfarin: Allopurinol may inhibit the metabolism of warfarin, possibly enhancing its anticoagulant effect. 12.5 Pharmacogenomics HLA-B*5801 allele The HLA-B*5801 allele is a genetic marker that has shown to be associated with risk of developing allopurinol tablets related hypersensitivity syndrome (DRESS) and SJS/TEN. The frequency of the HLA- B*58:01 allele ranges from 8 to 10% in Han Chinese populations, about 8% in Thai populations, and about 6% in Korean populations based upon published literature and available databases. The frequency of the HLA-B*58:01 allele is about 4% in Blacks, about 1 % to 2 % in indigenous peoples of the Americas and Hispanic populations, and < 1% in people from European descent and Japanese. Stevens-Johnson syndrome (SJS)/Toxic epidermal necrolysis (TEN) can still occur in patients who are found to be negative for HLA-B*5801 irrespective of ethnic origin."],"indications_and_usage":["1 INDICATIONS AND USAGE Allopurinol tablets are indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables) Limitations of Use Allopurinol tablets are not recommended for the treatment of asymptomatic hyperuricemia. Allopurinol tablets are a xanthine oxidase inhibitor indicated for the management of: Adult patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) ( 1 ) Adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels ( 1 ) Adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes ( 1 ) Limitations of Use Allopurinol tablets are not recommended for the treatment of asymptomatic hyperuricemia. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Skin Rash and Hypersensitivity: Allopurinol has been associated with serious and sometimes fatal dermatological reactions. Discontinue allopurinol tablets at the first appearance of skin rash or other signs of hypersensitivity reaction. ( 5.1 ) Gout Flares: May occur during initiation of treatment. Concurrent prophylactic treatment with colchicine or anti-inflammatory agents is recommended. ( 5.2 ) Nephrotoxicity: Allopurinol may affect kidney function. Patients with decreased kidney function require lower doses of allopurinol tablets. ( 5.3 ) Hepatoxicity: Cases of reversible hepatotoxicity have occurred. If signs and symptoms of hepatotoxicity develop, evaluate liver function. ( 5.4 ) Myelosuppression: Bone marrow suppression has been reported with allopurinol. ( 5.5 ) Potential Effect on Driving and Use of Machinery: Drowsiness, somnolence and dizziness have been reported in patients taking allopurinol tablets. ( 5.6 ) 5.1 Skin Rash and Hypersensitivity Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients taking allopurinol [see Adverse Reactions ( 6 )] . These reactions occur in approximately 5 in 10,000 (0.05%) patients taking allopurinol. Other serious hypersensitivity reactions that have been reported include exfoliative, urticarial and purpuric lesions, generalized vasculitis, and irreversible hepatotoxicity. Discontinue allopurinol tablets permanently at the first appearance of skin rash or other signs which may indicate a hypersensitivity reaction. The HLA-B*58:01 allele is a genetic marker for severe skin reactions indicative of hypersensitivity to allopurinol. Patients who carry the HLA-B*58:01 allele are at a higher risk of allopurinol hypersensitivity syndrome (AHS), but hypersensitivity reactions have been reported in patients who do not carry this allele. The frequency of this allele is higher in individuals of African, Asian (e.g., Han Chinese, Korean, Thai), and Native Hawaiian/Pacific Islander ancestry [see Clinical Pharmacology ( 12.5 )] . The use of allopurinol tablets is not recommended in HLA- B*58:01 positive patients unless the benefits clearly outweigh the risks. Consider screening for HLA-B*5801 before starting treatment with allopurinol tablets in patients from populations in which the prevalence of this HLA-B*5801 allele is known to be high. Screening is generally not recommended in patients from populations in which the prevalence of HLA-B*58:01 is low, or in current allopurinol users, as the risk of SJS/TEN/DRESS is largely confined to the first few months of therapy, regardless of HLA- B*58:01 status. Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. Concomitant use of the following drugs may also increase the risk of skin rash, which may be severe: bendamustine, ampicillin and amoxicillin [see Drug Interactions ( 7.1 )] . Discontinue allopurinol tablets immediately if a skin rash develops. Instruct patients to stop taking allopurinol tablets immediately and seek medical attention promptly if they develop a rash. 5.2 Gout Flares Gout flares have been reported during initiation of treatment with allopurinol tablets, even when normal or subnormal serum uric acid levels have been attained due to the mobilization of urates from tissue deposits. Even with adequate therapy with allopurinol tablets, it may require several months to deplete the uric acid pool sufficiently to achieve control of the flares. The flares typically become shorter and less severe after several months of therapy. In order to prevent gout flares when treatment with allopurinol tablets is initiated, concurrent prophylactic treatment with colchicine or an anti-inflammatory agent is recommended [see Dosage and Administration ( 2.2 )]. Advise patients to continue allopurinol tablets and prophylactic treatment even if gout flares occur, as it may take months to achieve control of gout flares. 5.3 Nephrotoxicity Treatment with allopurinol tablets may result in acute kidney injury due to formation of xanthine calculi or due to precipitation of urates in patients receiving concomitant uricosuric agents. Patients with pre-existing kidney disease, including chronic kidney disease or history of kidney stones, may be at increased risk for worsening of kidney function or acute kidney injury due to xanthine calculi while receiving treatment with allopurinol tablets. In patients receiving allopurinol tablets for the management of gout or the management of recurrent calcium oxalate calculi, monitor kidney function frequently during the early stages of allopurinol administration. Maintain fluid intake sufficient to yield a urinary output of at least 2 liters per day of neutral or, preferably, slightly alkaline urine to avoid the possibility of formation of xanthine calculi and help prevent renal precipitation of urates in patients receiving concomitant uricosuric agents. In patients receiving allopurinol tablets for the management of tumor lysis syndrome, monitor kidney function at least daily during the early stages of allopurinol administration. Maintain fluid intake sufficient to yield a urinary output of at least 2 liters per day in adults and at least 2 liters/m 2 /day (or at least 100 mL/m 2 /hour) in pediatric patients [see Dosage and Administration ( 2.4 )]. 5.4 Hepatotoxicity Cases of reversible clinical hepatotoxicity have occurred in patients taking allopurinol tablets, and in some patients, asymptomatic rises in serum alkaline phosphatase or serum transaminase have been observed. If anorexia, weight loss, or pruritus develop in patients on allopurinol tablets, evaluate liver enzymes. In patients with pre-existing liver disease, monitor liver enzymes periodically. Discontinue allopurinol tablets in patients with elevated liver enzymes. 5.5 Myelosuppression Myelosuppression, manifested by anemia, leukopenia or thrombocytopenia, has been reported in patients receiving allopurinol tablets. The cytopenias have occurred as early as 6 weeks up to 6 years after the initiation of therapy of allopurinol tablets. Concomitant use of allopurinol tablets with cytotoxic drugs associated with myelosuppression may increase the risk of myelosuppression. Monitor blood counts more frequently when cytotoxic drugs are used concomitantly [see Drug Interactions ( 7.2 )] . Concomitant use with allopurinol increases the exposure of either mercaptopurine or azathioprine which may increase the risk of myelosuppression. Reduce the dosage of mercaptopurine or azathioprine as recommended in their respective prescribing information when used concomitantly with allopurinol tablets [see Drug Interactions ( 7.2 )] . 5.6 Potential Effect on Driving and Use of Machinery Drowsiness, somnolence and dizziness have been reported in patients taking allopurinol tablets [see Adverse Reactions ( 6 )] . Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. Advise patients to avoid operation of automobiles or other dangerous machinery and activities made hazardous by decreased alertness when starting allopurinol tablets or increasing the dose, until they know how the drug affects them."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No evidence of tumorigenicity was observed in male or female mice or rats that received oral allopurinol for the majority of their life spans (greater than 88 weeks) at doses up to 20 mg/kg/day (0.1 and 0.2 times the MRHD on a mg/m 2 basis in mice and rats, respectively). Allopurinol tested negative in the following genotoxicity assays: the in vitro Ames assay, in vitro mouse lymphoma assay, and in vivo rat bone marrow micronucleus assay. Allopurinol administered intravenously to rats (50 mg/kg) was not incorporated into rapidly replicating intestinal DNA. No evidence of clastogenicity was observed in lymphocytes taken from patients treated with allopurinol (mean duration of treatment 40 months), or in an in vitro assay with human lymphocytes. Allopurinol oral doses of 20 mg/kg/day had no effect on male or female fertility in rats or rabbits (approximately 0.2 or 0.5 times the MRHD on a mg/m 2 basis, respectively). 13.2 Animal Toxicology and/or Pharmacology"],"drug_interactions_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"485.8pt\"/><col/><tbody><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Capecitabine</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Concomitant use with allopurinol may decrease concentration of capecitabine&#x2019;s active metabolites, which may decrease capecitabine efficacy.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Avoid the use of allopurinol tablets during treatment with capecitabine.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Chlorpropamide</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Allopurinol tablets prolong the half-life of chlorpropamide as both compete for renal tubular excretion. In patients with renal insufficiency, the risk of hypoglycemia may be increased due to this mechanism.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Monitor patients with renal insufficiency for hypoglycemia when administering chlorpropamide and allopurinol tablets concomitantly.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Cyclosporine</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Concomitant use of allopurinol increases cyclosporine concentrations, which may increase the risk of adverse reactions.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Increase frequency of monitoring cyclosporine concentrations as reflected in its prescribing information and modify the dosage of cyclosporine as appropriate when used concomitantly with allopurinol tablets.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Cyclophosphamide and Other Cytotoxic Agents</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Concomitant use of allopurinol with cyclophosphamide and other cytotoxic agents (doxorubicin, bleomycin, procarbazine, mechloroethamine) increases bone marrow suppression among patients with neoplastic disease, except leukemia.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Blood count monitoring and regular physician follow-up are recommended.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Dicumarol</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Allopurinol tablets prolong the half-life of the anticoagulant, dicumarol. The mechanism of this drug interaction has not been established but should be noted when allopurinol tablets are given to patients already on dicumarol therapy.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Monitor prothrombin time. Adjust the dosage of dicumarol accordingly when allopurinol tablets are added to anticoagulant therapy.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Fluorouracil</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Based on non-clinical data, allopurinol may decrease anti-tumor activity due to suppression of phosphorylation of 5-fluorouracil.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Concomitant administration with fluorouracil should be avoided.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Mercaptopurine or Azathioprine</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Allopurinol inhibits xanthine oxidase mediated metabolism of mercaptopurine and azathioprine. Concomitant use of allopurinol increases the exposure of either mercaptopurine or azathioprine which may increase the risk of their adverse reactions, including myelosuppression <content styleCode=\"italics\">[see Warnings and Precautions <linkHtml href=\"#LINK_fd9886f5-9465-4f9f-aa6a-8d45a3b08a57\">5.5</linkHtml>].</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>In patients receiving mercaptopurine or azathioprine, the concomitant administration of 300 mg to 600 mg of allopurinol tablets per day will require a reduction in dose to approximately one third to one fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Pegloticase</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Concomitant use of allopurinol tablets and pegloticase may potentially blunt the rise of serum uric acid levels and increase the risk of pegloticase related anaphylaxis in patients whose uric acid level increase to above 6 mg/dL.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Discontinue and do not institute allopurinol tablets therapy during treatment with pegloticase.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Theophylline</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Concomitant use of allopurinol doses greater than or equal to 600 mg/day may decrease the clearance of theophylline.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Monitor and adjust theophylline doses as reflected in the prescribing information.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Uricosuric Drugs</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Uricosuric agents increase the excretion of the active allopurinol metabolite oxypurinol. Concomitant use with uricosuric agents decreases oxypurinol exposure which may reduce the inhibition of xanthine oxidase by oxypurinol and increases the urinary excretion of uric acid.</paragraph><paragraph>The net effect of such combined therapy may be useful in some patients in achieving minimum serum uric acid levels provided the total urinary uric acid load does not exceed the competence of the patient&apos;s kidney function.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Monitor uric acid levels due to the increased chance of hypouricemic effects.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"bold\">Warfarin</content></paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Clinical Impact</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Allopurinol may inhibit the metabolism of warfarin, possibly enhancing its anticoagulant effect.</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph><content styleCode=\"italics\">Intervention</content></paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Monitor patients on concomitant therapy for excessive anticoagulation. Assess INR frequently and adjust warfarin dosage accordingly when allopurinol is added to warfarin therapy.</paragraph></td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Administration Advise patients to take allopurinol tablets after meals to minimize gastric irritation. If a single dose of allopurinol tablets is occasionally forgotten, there is no need to double the dose at the next scheduled time. Skin Rash and Hypersensitivity Inform patients that allopurinol tablets may increase the risk of serious and sometimes fatal dermatologic reactions. Instruct patients to discontinue allopurinol tablets and to seek medical attention immediately, at the first sign of a skin rash, blisters, fever, painful urination, blood in the urine, irritation of the eyes, swelling of the lips or mouth, or other signs and symptoms of hypersensitivity reactions [see Warnings and Precautions ( 5.1 )]. Gout Flares During Treatment With Allopurinol Tablets Inform patients that gout flares may occur during initiation of treatment with allopurinol tablets, even when their serum uric acid is normal. Concurrent use of additional medications such as colchicine or other anti-inflammatory agents can prevent gout flares. Advise patients to continue treatment with both, allopurinol tablets and the prophylactic therapy as prescribed, even if gout flares occur. Reassure them that it may take months to achieve control of the flares but the flares typically become shorter and less severe after several months of therapy [see Warnings and Precautions ( 5.2 )] . Nephrotoxicity Inform patients that allopurinol tablets may affect kidney function. Advise them to increase fluid intake during therapy (i.e., for adults, at least 2 liters of liquids per day) and to stay well hydrated to prevent kidney stones [see Warnings and Precautions ( 5.3 )] . Hepatotoxicity Inform patients of the risk of hepatotoxicity and to report to their healthcare provider any signs and symptoms of liver failure, including jaundice, pruritus, bleeding, bruising, or anorexia [see Warnings and Precautions ( 5.4 )]. Myelosuppression Advise patients of the risk of myelosuppression and to report any signs and symptoms of infection, fever, bleeding, shortness of breath, or significant fatigue to their healthcare provider [see Warnings and Precautions ( 5.5 )]. Potential Effect on Driving and Use of Machinery Inform patients that drowsiness, somnolence and dizziness have been reported in patients taking allopurinol tablets. Inform also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. Advise patients to avoid operation of automobiles or other dangerous machinery and activities made hazardous by decreased alertness when starting allopurinol tablets or increasing the dose, until they know how the drug affects them [see Warnings and Precautions ( 5.6 )] . Risks Associated with Use of Concomitant Medications Inform patients that there are risks of adverse effects when allopurinol tablets is used with the following drugs: dicumarol, warfarin, sulfinpyrazone, mercaptopurine, azathioprine, ampicillin, amoxicillin, pegloticase, theophylline, and thiazide diuretics. Advise patients to disclose all medications in use and they should follow the instructions of their physician [see Drug Interactions ( 7.2 )] . Pregnancy Advise pregnant women of the potential risk to a fetus. Advise women to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with allopurinol tablets [see Use in Specific Populations ( 8.1 )]. Lactation Advise women not to breastfeed during treatment with allopurinol tablets and for one week after the last dose [see Use in Specific Populations ( 8.2 )]. Dist. by: Par Pharmaceutical Chestnut Ridge, NY 10977 U.S.A. Mfg. by: Par Formulations Private Limited, 9/215, Pudupakkam, Kelambakkam - 603 103. Made in India Mfg. Lic. No.: TN00002121 OS2115H-01-74-04 Revised: 01/2024"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Gout : Prior to initiating treatment assess serum uric acid level, complete blood count, chemistry panel, liver and kidney function tests. Prophylactic treatment for gout flares is recommended. ( 2.1 , 2.2 ) Patients with normal kidney function: Initial dosage is 100 mg orally daily. Increase by 100 mg weekly increments until serum uric acid of 6 mg/dl or less is reached (maximum 800 mg daily). ( 2.3 ) Patients with impaired kidney function: The initial dosage is 50 mg orally daily. Follow recommendations for titration in patients with renal impairment until target serum uric acid level is reached. ( 2.6 ) See complete information in the Full Prescribing Information (FPI). Hyperuricemia Associated with Cancer Therapy : The recommended dosage is: Adults: 300 mg to 800 mg orally daily. Pediatric patients: 100 mg/m 2 orally every 8 hours to 12 hours (10 mg/kg/day, maximum 800 mg/day) See complete information in the FPI. ( 2.4 , 2.6 ) Recurrent Calcium Oxalate Calculi : The recommended initial dosage in patients with normal kidney function is 200 mg to 300 mg orally daily. ( 2.5 ) Dosage in Patients with Renal Impairment: See FPI for dosage modifications in patients with renal impairment. ( 2.6 ) 2.1 Recommended Testing Prior to Treatment Initiation Prior to initiating treatment with allopurinol tablets in patients with gout, assess the following baseline tests: serum uric acid level, complete blood count, chemistry panel, liver function tests (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin), kidney function tests (serum creatinine and eGFR). 2.2 Recommended Prophylaxis for Gout Flares Gout flares may occur after initiation of allopurinol tablets due to changing serum uric acid levels resulting in mobilization of urate from tissue deposits. Flare prophylaxis with colchicine or an anti- inflammatory agent according to practice guidelines is recommended upon initiation of allopurinol tablets. While adjusting the dosage of allopurinol tablets in patients who are being treated with colchicine and/or anti-inflammatory agents, continue flare prophylaxis drugs until serum uric acid has been normalized and the patient has been free of gout flares for several months. If a gout flare occurs during allopurinol tablets treatment, allopurinol tablets need not be discontinued. Manage the gout flare concurrently, as appropriate for the individual patient [see Warnings and Precautions ( 5.2 )]. 2.3 Recommended Dosage for Gout The initial recommended dosage for the management of gout is 100 mg orally daily, with weekly increments of 100 mg, until a serum uric acid level of 6 mg/dL or less is reached. Initiating treatment with lower dosages of allopurinol tablets and titrating slowly, decreases the risk of gout flares and drug induced serious adverse reactions. In patients with renal impairment the initial dosage is 50 mg orally daily with lower dose increases until serum uric acid level of 6 mg/dL or less is reached. For complete dosage recommendations for patients with renal impairment see Table 1 [see Dosage and Administration ( 2.6 )]. The minimal effective dosage is 100 mg to 200 mg daily and the maximal recommended dosage is 800 mg daily. The appropriate dosage may be administered in divided doses or as a single equivalent dose with the 300 mg tablet. Doses in excess of 300 mg should be administered in divided doses. Monitor patients’ kidney function during the early stages of administration of allopurinol tablets and decrease the dosage or withdraw the drug if persistent abnormalities in kidney function occur [see Dosage and Administration (2.6), Warnings and Precautions (5.3), Use in Specific Populations ( 8.6 )]. The dosage of allopurinol tablets to achieve control of gout varies with the severity of the disease. In general, gout control is achieved with 200 mg to 300 mg daily in patients with mild gout, and with 400 mg to 600 mg daily in patients with moderate to severe tophaceous gout. Gout attacks usually become shorter and less severe after several months of therapy. If a dose of allopurinol tablets is missed, there is no need to double the dose at the next scheduled time. Allopurinol tablets is generally better tolerated if taken following meals. A fluid intake sufficient to yield a daily urinary output of at least 2 liters and the maintenance of a neutral or preferably, slightly alkaline urine are desirable. Inform patients of the possibility of gout flares [see Warnings and Precautions ( 5.2 )]. Instruct them to remain on allopurinol tablets if this occurs and to increase fluid intake during therapy to prevent kidney stones. Concurrent Use of Uricosuric Agents Some patients, may benefit using uricosuric agents concurrently, to reduce serum uric acid to target levels. When transferring a patient from a uricosuric agent to allopurinol tablets, reduce the dose of the uricosuric agent over a period of several weeks and increase the dose of allopurinol tablets gradually to the required dose needed to maintain target serum uric acid level. 2.4 Recommended Dosage for Hyperuricemia Associated with Cancer Therapy Initiate therapy with allopurinol tablets 24 hours to 48 hours before the start of chemotherapy known to cause tumor cell lysis. Administer fluids sufficient to yield a daily urinary output of at least 2 liters in adults (at least 100 mL/m 2 /hour in pediatric patients) with a neutral or, preferably, slightly alkaline urine. The recommended dosage of allopurinol tablets is: Adult patients – 300 mg to 800 mg orally daily Pediatric patients - 100 mg/m 2 orally every 8 hours to 12 hours (10 mg/kg/day, maximum 800 mg/day). In patients with body surface area < 0.5 m 2 , consider using an alternative allopurinol formulation. The dosage of allopurinol tablets to maintain normal or near-normal serum uric acid varies with the severity of the disease. Monitor serum uric acid levels at least daily and administer allopurinol tablets at a dose and frequency to maintain the serum uric acid within the normal range. Discontinue allopurinol tablets when the risk of tumor lysis has abated (2 days to 3 days from start of chemotherapy). For complete dosage recommendations for patients with renal impairment, see Table 2 [see Dosage and Administration ( 2.6 )] . 2.5 Recommended Dosage for Management of Recurrent Calcium Oxalate Calculi in Hyperuricosuric Patients The recommended dosage for the management of recurrent calcium oxalate stones in hyperuricosuric patients is 200 mg to 300 mg orally daily in divided doses or as the single equivalent. This dose may be adjusted depending upon the resultant control of the hyperuricosuria based upon subsequent 24-hour urinary urate determinations. 2.6 Recommended Dosage in Patients with Renal Impairment The recommended initial dosages of allopurinol tablets in adult patients with renal impairment are shown in Tables 1 and 2 [see Use in Specific Populations ( 8.6 )] . Patients with Gout The recommended initial dosages in adult patients with gout with impaired kidney function are shown in Table 1 [see Use in Specific Populations ( 8.6 )]. Initiate treatment with a lower dose of allopurinol tablets and increase the dose gradually in 50 mg/day increments every 2 weeks to 4 weeks in patients with renal impairment to decrease the risk of drug induced serious adverse reactions. Use the lowest dose possible to achieve the desired effect on serum and/or urine uric acid. Monitor kidney function in gout patients with chronic kidney disease closely when initiating treatment with allopurinol tablets and decrease or withdraw the drug if increased abnormalities in kidney function appear and persist. Table 1. Recommended Initial Dosage in Adult Patients with Gout eGFR Initial Dosage > 60 mL/minute No dosage modification > 30 to 60 mL/minute 50 mg daily > 15 to 30 mL/minute 50 mg every other day 5 to 15 mL/minute 50 mg twice weekly < 5 mL/minute 50 mg once weekly The maximum dosage that should be used in patients with various levels of renal impairment is not defined at different eGFR levels. Patients with Recurrent Calcium Oxalate Calculi Data are insufficient to provide dosage recommendations for the treatment of recurrent calcium oxalate calculi in patients with renal impairment. Allopurinol and its metabolites are excreted by the kidney, and accumulation of the drug can occur in renal failure [see Warnings and Precautions ( 5.3 ) and Use in Specific Populations ( 8.6 )]. Hyperuricemia Associated with Cancer Therapy The recommended dosage of allopurinol tablets for the management of hyperuricemia associated with cancer therapy in adult patients with renal impairment is shown in Table 2 [see Use in Specific Populations ( 8.6 )]. Table 2. Recommended Dosage of Allopurinol Tablets in Adult Patients for Management of Hyperuricemia Associated with Cancer Therapy with Renal Impairment eGFR Recommended Dosage > 20 mL/min to 60 mL/min No dosage modification 10 mL/min to 20 mL/min 200 mg/day < 10 mL/min 100 mg/day On dialysis 50 mg every 12 hours, or 100 mg every 24 hours Treatment with allopurinol tablets has not been studied in pediatric patients with severe renal impairment (eGFR < 20 mL/min) or on dialysis. There is insufficient information to establish dosing for allopurinol tablets in pediatric patients with renal impairment. In these patients, consider the risks and potential benefits before initiating treatment with allopurinol tablets [see Warnings and Precautions ( 5.3 ) and Use in Specific Populations ( 8.6 )] ."],"drug_abuse_and_dependence":["9 DRUG ABUSE AND DEPENDENCE"],"spl_product_data_elements":["Allopurinol allopurinol ALLOPURINOL ALLOPURINOL SILICON DIOXIDE FD&C YELLOW NO. 6 LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE SODIUM STARCH GLYCOLATE TYPE A POTATO 2084;V allopurinol-structure"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Allopurinol tablets, USP have functional scoring and are available in the following strengths: 100 mg: White, round, flat face, beveled edge tablets. The upper layer is bisected and debossed with “2083/V”. The lower layer is plain. 300 mg: Orange, round and biconvex tablets. The upper layer is bisected and debossed with “2084/V”. The lower layer is plain. Tablets: 100 mg and 300 mg, functionally scored"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. ( 8.1 ) Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings in animals, allopurinol tablets may cause fetal harm when administered to a pregnant woman. Adverse developmental outcomes have been described in exposed animals (see Data). Allopurinol and its metabolite oxypurinol have been shown to cross the placenta following administration of maternal allopurinol. Available limited published data on allopurinol use in pregnant women do not demonstrate a clear pattern or increase in frequency of adverse developmental outcomes. Among approximately 50 pregnancies described in published literature, 2 infants with major congenital malformations have been reported with following maternal allopurinol exposure. Advise pregnant women of the potential risk to a fetus. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data Experience with allopurinol tablets during human pregnancy has been limited partly because women of reproductive age rarely require treatment with allopurinol tablets. A case report published in 2011 described the outcome of a full-term pregnancy in a 35-year-old woman who had recurrent kidney stones since age 18 who took allopurinol throughout the pregnancy. The child had multiple complex birth defects and died at 8 days of life. A second report in 2013 provided data on 31 prospectively ascertained pregnancies involving mothers exposed to allopurinol for varying durations during the first trimester. The overall rate of major fetal malformations and spontaneous abortions was reported to be within the normal expected range; however, one child had severe malformations similar to those described in the cited earlier case report. Animal Data There was no evidence of fetotoxicity or teratogenicity in rats or rabbits treated during the period of organogenesis with oral allopurinol at doses up to 200 mg/kg/day and up to 100 mg/kg/day, respectively (about 2.4 times the human dose on a mg/m 2 basis). However, there is a published report in pregnant mice that single intraperitoneal doses of 50 mg/kg or 100 mg/kg (about 0.3 or 0.6 times the human dose on a mg/m 2 basis) of allopurinol on gestation days 10 or 13 produced significant increases in fetal deaths and teratogenic effects (cleft palate, harelip, and digital defects). It is uncertain whether these findings represented a fetal effect or an effect secondary to maternal toxicity. 8.2 Lactation Risk Summary Allopurinol and oxypurinol are present in human milk. Based on information from a single case report, allopurinol and its active metabolite, oxypurinol, were detected in the milk of a mother receiving 300 mg of allopurinol daily at 5 weeks postpartum. The estimated relative infant dose were 0.14 mg/kg and 0.2 mg/kg of allopurinol and between 7.2 mg/kg to 8 mg/kg of oxypurinol daily. There was no report of effects of allopurinol on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatments with allopurinol tablets and for one week after the last dose. 8.3 Nursing Mothers 8.4 Pediatric Use Hyperuricemia Associated with Cancer Therapy The safety and effectiveness of allopurinol for the management of pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels have been established in approximately 200 pediatric patients. The efficacy and safety profile observed in this patient population were similar to that observed in adults. Primary or Secondary Gout The safety and effectiveness of allopurinol tablets have not been established for the treatment of signs and symptoms of primary or secondary gout in pediatric patients. Recurrent Calcium Oxalate Calculi The safety and effectiveness of allopurinol tablets have not been established for the management of pediatric patients with recurrent calcium oxalate calculi. Inborn Errors of Metabolism The safety and effectiveness of allopurinol tablets have not been established in pediatric patients with rare inborn errors of purine metabolism. 8.5 Geriatric Use 8.6 Renal Impairment Allopurinol tablets and its primary active metabolite, oxipurinol, are eliminated by the kidneys; therefore, changes in renal function have a profound effect on exposure. In patients with decreased renal function or who have concurrent illnesses which can affect renal function, perform periodic laboratory parameters of renal function and reassess the patient's dosage of allopurinol tablets [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.3 )]."],"dosage_and_administration_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"221.1pt\"/><col width=\"229.3pt\"/><tbody><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>eGFR</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Initial Dosage</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>&gt; 60 mL/minute</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>No dosage modification</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>&gt; 30 to 60 mL/minute</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>50 mg daily</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>&gt; 15 to 30 mL/minute</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>50 mg every other day</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>5 to 15 mL/minute</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>50 mg twice weekly</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>&lt; 5 mL/minute</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>50 mg once weekly</paragraph></td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\"><col width=\"199.5pt\"/><col width=\"268.8pt\"/><tbody><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>eGFR</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>Recommended Dosage</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>&gt; 20 mL/min to 60 mL/min</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>No dosage modification</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>10 mL/min to 20 mL/min</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>200 mg/day</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>&lt; 10 mL/min</paragraph></td><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>100 mg/day</paragraph></td></tr><tr><td styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>On dialysis</paragraph></td><td align=\"center\" styleCode=\" Botrule Toprule Lrule Rrule\"><paragraph>50 mg every 12 hours, or</paragraph><paragraph>100 mg every 24 hours</paragraph></td></tr></tbody></table>"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology"],"package_label_principal_display_panel":["Allopurinol Tablets 300 mg Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility No evidence of tumorigenicity was observed in male or female mice or rats that received oral allopurinol for the majority of their life spans (greater than 88 weeks) at doses up to 20 mg/kg/day (0.1 and 0.2 times the MRHD on a mg/m 2 basis in mice and rats, respectively). Allopurinol tested negative in the following genotoxicity assays: the in vitro Ames assay, in vitro mouse lymphoma assay, and in vivo rat bone marrow micronucleus assay. Allopurinol administered intravenously to rats (50 mg/kg) was not incorporated into rapidly replicating intestinal DNA. No evidence of clastogenicity was observed in lymphocytes taken from patients treated with allopurinol (mean duration of treatment 40 months), or in an in vitro assay with human lymphocytes. Allopurinol oral doses of 20 mg/kg/day had no effect on male or female fertility in rats or rabbits (approximately 0.2 or 0.5 times the MRHD on a mg/m 2 basis, respectively)."]},"tags":[{"label":"Xanthine Oxidase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Xanthine dehydrogenase/oxidase","category":"target"},{"label":"XDH","category":"gene"},{"label":"ADORA2A","category":"gene"},{"label":"HPRT1","category":"gene"},{"label":"M04AA01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Articular gout","category":"indication"},{"label":"Calcium renal calculus","category":"indication"},{"label":"Chemotherapy-Induced Hyperuricemia","category":"indication"},{"label":"Gout","category":"indication"},{"label":"Hyperuricemia","category":"indication"},{"label":"Recurrent Calcium Renal Calculi","category":"indication"},{"label":"Casper Pharma Llc","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antioxidants","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Free Radical Scavengers","category":"pharmacology"},{"label":"Gout Suppressants","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["BOXED WARNING"],"safetySignals":[{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"8450 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"7996 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"7704 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"7075 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"6686 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"6571 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"6301 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"5981 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"5594 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"5510 reports"}],"drugInteractions":[{"url":"/drug/amoxicillin","drug":"amoxicillin","action":"Monitor closely","effect":"May interact with Amoxicillin","source":"DrugCentral","drugSlug":"amoxicillin"},{"url":"/drug/azathioprine","drug":"azathioprine","action":"Avoid combination","effect":"May interact with Azathioprine","source":"DrugCentral","drugSlug":"azathioprine"},{"url":"/drug/didanosine","drug":"didanosine","action":"Monitor closely","effect":"May interact with Didanosine","source":"DrugCentral","drugSlug":"didanosine"},{"url":"/drug/mercaptopurine","drug":"mercaptopurine","action":"Avoid combination","effect":"May interact with Mercaptopurine","source":"DrugCentral","drugSlug":"mercaptopurine"},{"url":"/drug/warfarin","drug":"warfarin","action":"Monitor closely","effect":"May interact with Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[{"effect":"Drug reaction with eosinophilia and systemic symptoms","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Acute kidney injury","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Anaemia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Hyperkalaemia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Renal failure","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Toxic epidermal necrolysis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Gout","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Febrile neutropenia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Pemphigus","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Maternal exposure during pregnancy","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Stevens-Johnson syndrome","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Systemic lupus erythematosus","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Alopecia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Tumour lysis syndrome","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3}],"contraindications":["Patients with a history of hypersensitivity reaction to allopurinol.","Patients with a known hypersensitivity to any of the ingredients of allopurinol tablets."],"specialPopulations":{"Pregnancy":"May cause fetal harm. Allopurinol and its metabolite oxypurinol have been shown to cross the placenta following administration of maternal allopurinol. The estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.","Geriatric use":"Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.","Paediatric use":"Allopurinol is rarely indicated for use in children with the exception of those with hyperuricemia secondary to malignancy or to certain rare inborn errors of purine metabolism.","Hepatic impairment":"Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy."}},"trials":[],"aliases":[],"company":"Casper Pharma Llc","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0513/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$19","description":"ALLOPURINOL 100 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALLOPURINOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:21:45.546721+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Allopurinol","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:21:53.780441+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:21:52.220049+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:21:44.181763+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALLOPURINOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:21:52.922387+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:42.191986+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:42.192052+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"BOXED WARNING","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:42.192123+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:21:54.867036+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Xanthine dehydrogenase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:21:53.780378+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1467/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:21:53.683532+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:22:01.002927+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA075798","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:42.192134+00:00"}},"allNames":"aloprim","offLabel":[],"synonyms":["zyloprim","allopurinol","tautomeric mixture of 1H-pyrazolo[3,4-d]pyrimidin-4-ol and 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one","allopurinol sodium"],"timeline":[{"date":"1966-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PROMETHEUS LABS to Casper Pharma Llc"},{"date":"1966-08-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Prometheus Labs)"},{"date":"1984-09-28","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Watson Labs)"},{"date":"1984-11-16","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Watson Labs)"},{"date":"1986-04-14","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 5 manufacturers approved"}],"aiSummary":"Aloprim (Allopurinol) is a small molecule xanthine oxidase inhibitor developed by Prometheus Labs and currently owned by Casper Pharma Llc. It targets xanthine dehydrogenase/oxidase to treat various conditions, including articular gout, calcium renal calculus, and chemotherapy-induced hyperuricemia. FDA-approved in 1966, Aloprim is now off-patent with 22 generic manufacturers. Key safety considerations include its short half-life of 0.8 hours and moderate bioavailability of 53%. As an off-patent medication, it is widely available in the market.","brandName":"Aloprim","ecosystem":[{"indication":"Articular gout","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"canakinumab","slug":"canakinumab","company":"Novartis Pharms"},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""}],"globalPrevalence":41000000},{"indication":"Calcium renal calculus","otherDrugs":[{"name":"potassium citrate","slug":"potassium-citrate","company":"Mission Pharma"},{"name":"sodium phosphate, monobasic","slug":"sodium-phosphate,-monobasic","company":""},{"name":"sodium phosphate, monobasic, monohydrate","slug":"sodium-phosphate,-monobasic,-monohydrate","company":"Salix Pharms"}],"globalPrevalence":null},{"indication":"Chemotherapy-Induced Hyperuricemia","otherDrugs":[],"globalPrevalence":null},{"indication":"Gout","otherDrugs":[{"name":"colchicine","slug":"colchicine","company":"Merck"},{"name":"indomethacin","slug":"indomethacin","company":""},{"name":"naproxen","slug":"naproxen","company":"Roche Palo"},{"name":"pegloticase","slug":"pegloticase","company":"Crealta Pharms Llc"}],"globalPrevalence":41000000},{"indication":"Hyperuricemia","otherDrugs":[{"name":"febuxostat","slug":"febuxostat","company":"Takeda Pharms Usa"},{"name":"lesinurad","slug":"lesinurad","company":"Ardea Biosciences Inc"},{"name":"probenecid","slug":"probenecid","company":""},{"name":"rasburicase","slug":"rasburicase","company":"Sanofi Synthelabo"}],"globalPrevalence":null},{"indication":"Recurrent Calcium Renal Calculi","otherDrugs":[],"globalPrevalence":null},{"indication":"Uric Acid Nephropathy Gout","otherDrugs":[],"globalPrevalence":41000000},{"indication":"Uric acid renal calculus","otherDrugs":[{"name":"potassium citrate","slug":"potassium-citrate","company":"Mission Pharma"}],"globalPrevalence":null}],"mechanism":{"target":"Xanthine dehydrogenase/oxidase","novelty":"Follow-on","targets":[{"gene":"XDH","source":"DrugCentral","target":"Xanthine dehydrogenase/oxidase","protein":"Xanthine dehydrogenase/oxidase"},{"gene":"ADORA2A","source":"DrugCentral","target":"Adenosine receptor A2a","protein":"Adenosine receptor A2a"},{"gene":"HPRT1","source":"DrugCentral","target":"Hypoxanthine-guanine phosphoribosyltransferase","protein":"Hypoxanthine-guanine phosphoribosyltransferase"}],"moaClass":"Xanthine Oxidase Inhibitors","modality":"Small Molecule","drugClass":"Xanthine Oxidase Inhibitor [EPC]","explanation":"Allopurinol is structural analogue of the natural purine base, hypoxanthine. Allopurinol and its oxypurinol metabolite inhibitor xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in humans. Allopurinol does not disrupt the biosynthesis of purines.The action of oral allopurinol differs from that of uricosuric agents, which lower the serum uric acid level by increasing urinary excretion of uric acid. Allopurinol reduces both the serum and urinary uric acid levels by inhibiting the formation of uric acid. The use of allopurinol to block the formation of urates avoids the hazard of increased renal excretion of uric acid posed by uricosuric drugs.","oneSentence":"Aloprim works by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid in the body.","technicalDetail":"Allopurinol competitively inhibits xanthine oxidase, preventing the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing uric acid production in the body."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Allopurinol","title":"Allopurinol","extract":"Allopurinol is a medication used to decrease high blood uric acid levels. It is specifically used to prevent gout, prevent specific types of kidney stones and for the high uric acid levels that can occur with chemotherapy. It is taken orally or intravenously.","wiki_history":"== History ==\nAllopurinol was first synthesized and reported in 1956 by Roland K. Robins (1926–1992), in a search for antineoplastic agents.   Allopurinol inhibits the breakdown (catabolism) of the thiopurine drug mercaptopurine, and was later tested by Wayne Rundles in collaboration with Gertrude Elion's lab at Wellcome Research Laboratories to see if it could improve treatment of acute lymphoblastic leukemia by enhancing the action of mercaptopurine.  However, no improvement in leukemia response was noted with mercaptopurine-allopurinol co-therapy, so that work turned to other compounds and the team then started testing allopurinol as a potential therapeutic for gout.  Allopurinol was first marketed as a treatment for gout in 1966.","wiki_society_and_culture":"==Society and culture==\nthumb|Pure allopurinol is a white powder.\n\n===Formulations===\nAllopurinol is sold as an injection for intravenous use and as a tablet.\n\n===Brands===\nthumb|upright=0.6|A package of Milurit 100mg (a brand of allopurinol)\nAllopurinol has been marketed in the United States since 19 August 1966, when it was first approved by FDA under the trade name Zyloprim.  Allopurinol was marketed at the time by Burroughs Wellcome.  Allopurinol is a generic drug sold under a variety of brand names, including Allohexal, Allosig, Milurit, Alloril, Progout, Ürikoliz, Zyloprim, Zyloric, Zyrik, and Aluron."},"commercial":{"launchDate":"1966","_launchSource":"DrugCentral (FDA 1966-08-19, PROMETHEUS LABS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/124","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALLOPURINOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALLOPURINOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Allopurinol","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:37:47.741814","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:22:02.974924+00:00","fieldsConflicting":14,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"febuxostat","drugSlug":"febuxostat","fdaApproval":"2009-02-13","patentExpiry":"Sep 8, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"allopurinol","indications":{"approved":[{"name":"Articular gout","source":"DrugCentral","snomedId":48440001,"regulator":"FDA","eligibility":"patients with signs and symptoms of primary or secondary gout","usPrevalence":9200000,"globalPrevalence":41000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Calcium renal calculus","source":"DrugCentral","snomedId":427649000,"regulator":"FDA","eligibility":"patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients"},{"name":"Chemotherapy-Induced Hyperuricemia","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels"},{"name":"Gout","source":"DrugCentral","snomedId":90560007,"regulator":"FDA","eligibility":"patients with signs and symptoms of primary or secondary gout","usPrevalence":9200000,"globalPrevalence":41000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Hyperuricemia","source":"DrugCentral","snomedId":35885006,"regulator":"FDA","eligibility":"not recommended for the treatment of asymptomatic hyperuricemia"},{"name":"Recurrent Calcium Renal Calculi","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients"},{"name":"Uric Acid Nephropathy Gout","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"patients with signs and symptoms of primary or secondary gout","usPrevalence":9200000,"globalPrevalence":41000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Uric acid renal calculus","source":"DrugCentral","snomedId":274401005,"regulator":"FDA","eligibility":"patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients"}],"offLabel":[{"name":"Adjunctive treatment for bipolar disorder","source":"DrugCentral","drugName":"ALLOPURINOL","evidenceCount":8,"evidenceLevel":"emerging"},{"name":"Deficiency of adenine phosphoribosyltransferase","source":"DrugCentral","drugName":"ALLOPURINOL","evidenceCount":73,"evidenceLevel":"strong"},{"name":"Deficiency of ribose-phosphate pyrophosphokinase","source":"DrugCentral","drugName":"ALLOPURINOL","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Neonatal Phosphoribosylpyrophosphate Synthetase Superactivity","source":"DrugCentral","drugName":"ALLOPURINOL"}],"pipeline":[]},"currentOwner":"Casper Pharma Llc","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"febuxostat","brandName":"febuxostat","genericName":"febuxostat","approvalYear":"2009","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07089888","phase":"PHASE3","title":"A Study of Dotinurad Versus Allopurinol in Tophaceous Gout","status":"RECRUITING","sponsor":"Crystalys Therapeutics","startDate":"2025-08-04","conditions":["Tophaceous Gout"],"enrollment":250,"completionDate":"2027-12-31"},{"nctId":"NCT07089875","phase":"PHASE3","title":"A Study of Dotinurad Versus Allopurinol in Participants With Gout","status":"RECRUITING","sponsor":"Crystalys Therapeutics","startDate":"2025-08-01","conditions":["Gout"],"enrollment":500,"completionDate":"2027-11-29"},{"nctId":"NCT03776656","phase":"PHASE2","title":"Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-10-14","conditions":["Adenylosuccinate Lyase Deficiency"],"enrollment":8,"completionDate":"2022-06-17"},{"nctId":"NCT03150693","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2017-09-20","conditions":["B Acute Lymphoblastic Leukemia"],"enrollment":310,"completionDate":"2027-08"},{"nctId":"NCT04746989","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-01","conditions":["Gout"],"enrollment":294878,"completionDate":"2023-12-31"},{"nctId":"NCT05536349","phase":"PHASE2","title":"Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-12-20","conditions":["Leukemia"],"enrollment":60,"completionDate":"2028-04-25"},{"nctId":"NCT06669000","phase":"","title":"Time Required to Dissolve Urate Deposits","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-09-24","conditions":["Gout"],"enrollment":250,"completionDate":"2032-09-24"},{"nctId":"NCT05053659","phase":"PHASE1","title":"Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paolo Caimi, MD","startDate":"2022-06-20","conditions":["Relapsed Non Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma"],"enrollment":23,"completionDate":"2026-06"},{"nctId":"NCT04733079","phase":"NA","title":"Treat-to-target by Email During Urate-lowering Therapy in Gout","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-15","conditions":["Gout","Inflammatory Rheumatism","Hyperuricemia","Posology Adjustment"],"enrollment":204,"completionDate":"2026-12-31"},{"nctId":"NCT04621929","phase":"PHASE3","title":"Phentermine/Topiramate for Uric Acid Stones","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-03-31","conditions":["Obesity","Uric Acid Stones","Type 2 Diabetes Mellitus in Obese","Pre-Diabetes"],"enrollment":19,"completionDate":"2024-11-14"},{"nctId":"NCT07369622","phase":"PHASE4","title":"HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness","status":"NOT_YET_RECRUITING","sponsor":"Haiphong University of Medicine and Pharmacy","startDate":"2026-01-20","conditions":["Gout Initiating Urate-loweringUrate-lowering Therapy","Gout Arthritis","Gout and Hyperuricemia"],"enrollment":228,"completionDate":"2028-12-30"},{"nctId":"NCT07367971","phase":"PHASE1","title":"Drug-Drug Interaction Study of ABP-671 in Gout Patients","status":"NOT_YET_RECRUITING","sponsor":"Atom Therapeutics Co., Ltd","startDate":"2026-01-26","conditions":["Gout Chronic","Gout","DDI (Drug-Drug Interaction)"],"enrollment":20,"completionDate":"2026-08-31"},{"nctId":"NCT05888233","phase":"PHASE2","title":"Allopurinol Improves Heart Function in African Americans With Resistant Hypertension","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-09-30","conditions":["Heart Failure Preserved Ejection Fraction","Resistant Hypertension"],"enrollment":50,"completionDate":"2026-05-31"},{"nctId":"NCT07326839","phase":"NA","title":"Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT","status":"NOT_YET_RECRUITING","sponsor":"XueMei Guo","startDate":"2025-12-10","conditions":["Gout","Obesity"],"enrollment":120,"completionDate":"2027-11-09"},{"nctId":"NCT05818085","phase":"PHASE2,PHASE3","title":"Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout","status":"COMPLETED","sponsor":"Atom Therapeutics Co., Ltd","startDate":"2023-08-11","conditions":["Gout"],"enrollment":300,"completionDate":"2025-03-30"},{"nctId":"NCT05365477","phase":"PHASE4","title":"Empiric Versus Selective Prevention Strategies for Kidney Stone Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-08-04","conditions":["Kidney Stones","Nephrolithiasis"],"enrollment":56,"completionDate":"2025-10-17"},{"nctId":"NCT04875702","phase":"PHASE4","title":"Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-02-22","conditions":["Gout"],"enrollment":650,"completionDate":"2028-10-31"},{"nctId":"NCT07177898","phase":"NA","title":"ALLOPURINOL AND LISINOPRIL FOR DIABETIC KIDNEY PROTECTION: A COMPARATIVE STUDY IN NORMOURICEMIC TYPE 2 DIABETICS","status":"COMPLETED","sponsor":"Narowal Medical College","startDate":"2023-05-14","conditions":["Diabetic Kidney Disease (DKD)"],"enrollment":80,"completionDate":"2024-11-18"},{"nctId":"NCT05586971","phase":"PHASE3","title":"Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-03-30","conditions":["Gout","Hyperuricemia","Gout Flare","Tophi"],"enrollment":2202,"completionDate":"2025-05-06"},{"nctId":"NCT06276556","phase":"PHASE2,PHASE3","title":"Extension Study of ABP-671 in Participants With Gout","status":"TERMINATED","sponsor":"Atom Therapeutics Co., Ltd","startDate":"2024-04-22","conditions":["Gout"],"enrollment":43,"completionDate":"2024-09-05"},{"nctId":"NCT05805605","phase":"PHASE2","title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-01","conditions":["Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Biphenotypic Acute Leukemia","Undifferentiated Leukemia","Prolymphocytic Leukemia","Chronic Myelogenous Leukemia","Plasma Cell Leukemia","Myelodysplastic Syndromes","Leukemia, Myeloid","Myelodysplastic Syndrome With Excess Blasts-1","Burkitt Lymphoma","Relapsed T-Cell Lymphoma","Relapsed Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Marginal Zone Lymphoma","Follicular Lymphoma","Myeloproliferative Neoplasm","Myelofibrosis"],"enrollment":56,"completionDate":"2028-10-22"},{"nctId":"NCT05507723","phase":"NA","title":"Tight Control of Gouty Arthritis Compared to Usual Care","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2025-06-12","conditions":["Gout"],"enrollment":120,"completionDate":"2028-12-31"},{"nctId":"NCT04026776","phase":"EARLY_PHASE1","title":"Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-09-02","conditions":["Salt; Excess","Blood Pressure Disorders"],"enrollment":120,"completionDate":"2026-06"},{"nctId":"NCT07033533","phase":"PHASE1,PHASE2","title":"Allopurinol and Pathogenesis of Cirrhosis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-06-01","conditions":["Cirrhoses, Liver"],"enrollment":100,"completionDate":"2024-03-01"},{"nctId":"NCT06995339","phase":"PHASE2","title":"Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-05-30","conditions":["Gout"],"enrollment":60,"completionDate":"2026-12-20"},{"nctId":"NCT02953509","phase":"PHASE1,PHASE2","title":"Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-11-21","conditions":["Non Hodgkin Lymphoma"],"enrollment":178,"completionDate":"2024-03-25"},{"nctId":"NCT06966635","phase":"PHASE4","title":"Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-04-10","conditions":["Hyperuricemia or Gout","Nephrolithiasis"],"enrollment":312,"completionDate":"2026-04-30"},{"nctId":"NCT05734495","phase":"PHASE2","title":"Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-05-02","conditions":["Waldenstrom Macroglobulinemia"],"enrollment":42,"completionDate":"2033-01-25"},{"nctId":"NCT05665699","phase":"PHASE2","title":"Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout","status":"ACTIVE_NOT_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2023-04-17","conditions":["Gout"],"enrollment":80,"completionDate":"2025-12-30"},{"nctId":"NCT05601271","phase":"NA","title":"Effect of Allopurinol on Markers of Mineral and Bone Metabolism","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-03-01","conditions":["Chronic Kidney Diseases","Osteodystrophy","Uric Acid Concentration, Serum, Quantitative Trait Locus 7"],"enrollment":50,"completionDate":"2025-03-01"},{"nctId":"NCT01623492","phase":"","title":"Eisenmenger Quality Enhancement Research Initiative","status":"COMPLETED","sponsor":"Actelion","startDate":"2012-07-01","conditions":["Pulmonary Arterial Hypertension"],"enrollment":193,"completionDate":"2018-04-17"},{"nctId":"NCT05253833","phase":"PHASE2","title":"Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout","status":"COMPLETED","sponsor":"Arthrosi Therapeutics","startDate":"2022-08-12","conditions":["Gout","Arthritis, Gouty","Hyperuricemia","Gout Chronic"],"enrollment":42,"completionDate":"2024-10-28"},{"nctId":"NCT06056570","phase":"PHASE1,PHASE2","title":"Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia","status":"COMPLETED","sponsor":"Urica Therapeutics Inc.","startDate":"2023-10-04","conditions":["Gout","Hyperuricemia"],"enrollment":20,"completionDate":"2024-07-09"},{"nctId":"NCT04956432","phase":"PHASE3","title":"A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-06-15","conditions":["Gout"],"enrollment":779,"completionDate":"2024-08-23"},{"nctId":"NCT05943821","phase":"PHASE3","title":"The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2023-09-01","conditions":["Cardiovascular Diseases","Uric Acid"],"enrollment":1116,"completionDate":"2028-07-31"},{"nctId":"NCT05049863","phase":"PHASE1","title":"Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2023-02-27","conditions":["Small-cell Lung Cancer","Small Cell Lung Carcinoma"],"enrollment":17,"completionDate":"2024-11-17"},{"nctId":"NCT06622603","phase":"PHASE4","title":"The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-10-15","conditions":["Gout","Uric Acid"],"enrollment":59,"completionDate":"2026-10-14"},{"nctId":"NCT04217421","phase":"PHASE3","title":"Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass","status":"RECRUITING","sponsor":"dr. M.J.N.L. Benders","startDate":"2020-02-14","conditions":["Congenital Heart Disease in Children","Neuroprotection"],"enrollment":236,"completionDate":"2028-12-31"},{"nctId":"NCT02752633","phase":"PHASE4","title":"Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion","status":"COMPLETED","sponsor":"Landspitali University Hospital","startDate":"2013-05","conditions":["Adenine Phosphoribosyltransferase Deficiency"],"enrollment":9,"completionDate":"2015-05"},{"nctId":"NCT02579096","phase":"PHASE4","title":"CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2017-03-06","conditions":["Gout","Chronic Kidney Diseases"],"enrollment":950,"completionDate":"2021-04-15"},{"nctId":"NCT04699383","phase":"","title":"Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2021-02-15","conditions":["Cutaneous Leishmaniasis"],"enrollment":105,"completionDate":"2022-12-15"},{"nctId":"NCT05828836","phase":"PHASE2,PHASE3","title":"Allopurinol and Quality of Life in Liver Cirrhosis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-06-15","conditions":["Cirrhosis, Liver"],"enrollment":100,"completionDate":"2023-03-01"},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":["Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Plasma Cell Leukemia","Myelodysplastic Syndromes","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","B-Cell Lymphoma","Follicular Lymphoma","Lymphoplasmacytic Lymphoma","Mantle-Cell Lymphoma","Prolymphocytic Leukemia","Lymphoblastic Lymphoma","Burkitt's Lymphoma","Non-Hodgkin's Lymphoma","Multiple Myeloma","Myeloproliferative Syndromes","Hematological Diseases"],"enrollment":156,"completionDate":"2023-05-29"},{"nctId":"NCT00039130","phase":"PHASE2","title":"Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-05","conditions":["Leukemia","Lymphoma"],"enrollment":105,"completionDate":"2014-10"},{"nctId":"NCT00816413","phase":"PHASE1,PHASE2","title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-09","conditions":["Chronic Myeloproliferative Disorders","Leukemia","Lymphoma","Myelodysplastic Syndromes","Nonmalignant Neoplasm"],"enrollment":0,"completionDate":"2010-02"},{"nctId":"NCT05474560","phase":"PHASE4","title":"Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":["Non-Alcoholic Fatty Liver Disease","Hyperuricemia"],"enrollment":90,"completionDate":"2023-01-28"},{"nctId":"NCT03162653","phase":"PHASE3","title":"Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2018-03-25","conditions":["Encephalopathy, Hypoxic-Ischemic","Infant, Newborn, Diseases"],"enrollment":760,"completionDate":"2026-01-31"},{"nctId":"NCT03648996","phase":"PHASE2","title":"Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2018-11-01","conditions":["Diabetes Mellitus, Type 2","Hyperuricemia"],"enrollment":34,"completionDate":"2022-03-10"},{"nctId":"NCT04327024","phase":"PHASE2","title":"Study of Verinurad in Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-05-19","conditions":["Heart Failure With Preserved Ejection Fraction (HFpEF)"],"enrollment":159,"completionDate":"2022-04-29"},{"nctId":"NCT04550234","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-04-13","conditions":["Chronic Kidney Disease"],"enrollment":25,"completionDate":"2021-07-15"},{"nctId":"NCT05545670","phase":"PHASE2,PHASE3","title":"Allopurinol to Prevent Cirrhosis Related Morbidities","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-06-15","conditions":["Cirrhosis"],"enrollment":100,"completionDate":"2023-03-01"},{"nctId":"NCT05511766","phase":"PHASE2,PHASE3","title":"Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-11-15","conditions":["Cirrhosis","Hepatic Encephalopathy","Ascites","Varices","SBP - Spontaneous Bacterial Peritonitis"],"enrollment":150,"completionDate":"2025-01-30"},{"nctId":"NCT04213534","phase":"","title":"The Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients：A Prospective Cohort Study","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2020-10-10","conditions":["Gout"],"enrollment":60,"completionDate":"2023-12"},{"nctId":"NCT04532918","phase":"PHASE1","title":"Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-09-10","conditions":["Chronic Kidney Disease"],"enrollment":14,"completionDate":"2020-11-23"},{"nctId":"NCT00199043","phase":"PHASE3","title":"Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-05","conditions":["Adult Acute Lymphocytic Leukemia","High-grade Lymphoma"],"enrollment":80,"completionDate":"2008-05"},{"nctId":"NCT03990363","phase":"PHASE2","title":"A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-07-23","conditions":["Chronic Kidney Disease"],"enrollment":861,"completionDate":"2021-11-22"},{"nctId":"NCT05360628","phase":"EARLY_PHASE1","title":"Evaluation of PK and Safety of D-0120 and Allopurinol","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2021-11-01","conditions":["Healthy"],"enrollment":20,"completionDate":"2022-07-23"},{"nctId":"NCT05540184","phase":"PHASE4","title":"Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2022-09-19","conditions":["AKI - Acute Kidney Injury"],"enrollment":124,"completionDate":"2025-09"},{"nctId":"NCT03745729","phase":"PHASE4","title":"Allopurinol in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2019-03-01","conditions":["Acute Coronary Syndrome"],"enrollment":162,"completionDate":"2022-07-15"},{"nctId":"NCT03336203","phase":"PHASE4","title":"The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)","status":"UNKNOWN","sponsor":"Medical Practice Prof D. Ivanov","startDate":"2017-10-30","conditions":["Gout","CKD Stage 1-4","SUA Level (>8 mg/dL; 480 µmol/L)"],"enrollment":2,"completionDate":"2022-12-31"},{"nctId":"NCT03570983","phase":"PHASE2","title":"A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion","status":"UNKNOWN","sponsor":"Swedish Medical Center","startDate":"2018-09-05","conditions":["Multiple Myeloma"],"enrollment":100,"completionDate":"2024-12"},{"nctId":"NCT02046694","phase":"EARLY_PHASE1","title":"A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-01-06","conditions":["Acute Lymphoblastic Leukemia (ALL)"],"enrollment":34,"completionDate":"2020-04-06"},{"nctId":"NCT04052932","phase":"PHASE3","title":"A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-16","conditions":["Gout"],"enrollment":594,"completionDate":"2021-07-14"},{"nctId":"NCT05414669","phase":"PHASE4","title":"Allopurinol Effect on MDA,NO,KIM-1 Urine Levels, RI and Renal Elastography in Kidney Stone Patients Post ESWL","status":"COMPLETED","sponsor":"Sanglah General Hospital","startDate":"2020-08-06","conditions":["Kidney Calculi"],"enrollment":35,"completionDate":"2021-04-20"},{"nctId":"NCT00061945","phase":"PHASE1,PHASE2","title":"Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-06","conditions":["Acute Undifferentiated Leukemia","B-cell Adult Acute Lymphoblastic Leukemia","B-cell Childhood Acute Lymphoblastic Leukemia","L1 Adult Acute Lymphoblastic Leukemia","L1 Childhood Acute Lymphoblastic Leukemia","L2 Adult Acute Lymphoblastic Leukemia","L2 Childhood Acute Lymphoblastic Leukemia","Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia","Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia","Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia","T-cell Adult Acute Lymphoblastic Leukemia","T-cell Childhood Acute Lymphoblastic Leukemia","Untreated Adult Acute Lymphoblastic Leukemia","Untreated Childhood Acute Lymphoblastic Leukemia"],"enrollment":302,"completionDate":"2012-10"},{"nctId":"NCT03465527","phase":"PHASE2","title":"Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL","status":"COMPLETED","sponsor":"Kosin University Gospel Hospital","startDate":"2017-04-13","conditions":["Diffuse Large B Cell Lymphoma"],"enrollment":37,"completionDate":"2021-07-13"},{"nctId":"NCT03334318","phase":"","title":"PERL Continuous Glucose Monitoring (CGM) Study","status":"COMPLETED","sponsor":"Joslin Diabetes Center","startDate":"2017-10-01","conditions":["Diabetic Nephropathies"],"enrollment":175,"completionDate":"2021-12-31"},{"nctId":"NCT04256629","phase":"PHASE1","title":"A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-03-03","conditions":["Healthy Volunteers (Intended Indication: Chronic Kidney Disease)"],"enrollment":24,"completionDate":"2020-08-21"},{"nctId":"NCT05193838","phase":"","title":"Effect of Allopurinol on Left Ventricular Function in Children With Dilated Cardiomyopathy","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-05-01","conditions":["Dilated Cardiomyopathy"],"enrollment":100,"completionDate":"2023-07"},{"nctId":"NCT02214407","phase":"PHASE3","title":"Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML","status":"COMPLETED","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2014-10-14","conditions":["MDS"],"enrollment":170,"completionDate":"2021-08-16"},{"nctId":"NCT02122718","phase":"PHASE4","title":"XILO-FIST, the Effect of Allopurinol on the Brain Heart and Blood Pressure After Stroke","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2014-05","conditions":["Ischaemic Stroke"],"enrollment":464,"completionDate":"2021-02"},{"nctId":"NCT04040816","phase":"PHASE2","title":"Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients","status":"COMPLETED","sponsor":"Shanton Pharma Co., Ltd.","startDate":"2019-01-01","conditions":["Gout","Hyperuricemia"],"enrollment":40,"completionDate":"2020-08-30"},{"nctId":"NCT03226899","phase":"PHASE4","title":"A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment","status":"TERMINATED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2017-07-19","conditions":["Gout","Chronic Kidney Disease (CKD)"],"enrollment":242,"completionDate":"2019-02-25"},{"nctId":"NCT00000658","phase":"PHASE3","title":"A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Lymphoma, Non-Hodgkin","HIV Infections"],"enrollment":250,"completionDate":"1996-02"},{"nctId":"NCT00000703","phase":"NA","title":"Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Lymphoma, Non-Hodgkin","HIV Infections"],"enrollment":45,"completionDate":"1990-03"},{"nctId":"NCT04983160","phase":"PHASE2","title":"Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2014-02-26","conditions":["Chronic Kidney Disease"],"enrollment":22,"completionDate":"2016-04-29"},{"nctId":"NCT03865407","phase":"PHASE2","title":"Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2019-03-10","conditions":["Hyperuricemia","Chronic Kidney Diseases"],"enrollment":17,"completionDate":"2020-10-07"},{"nctId":"NCT04853160","phase":"","title":"Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-08-15","conditions":["Gout","Cardiovascular Diseases"],"enrollment":24046,"completionDate":"2021-01-05"},{"nctId":"NCT04853615","phase":"","title":"SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?","status":"UNKNOWN","sponsor":"Fayoum University","startDate":"2021-07-01","conditions":["SGLT2i Kideny Protection Against Contrast in Diabetic Kidney"],"enrollment":800,"completionDate":"2024-08-01"},{"nctId":"NCT04072471","phase":"","title":"Post-Authorisation Safety Study of Lesinurad","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2021-01-29","conditions":["Gout","Hyperuricemia"],"enrollment":0,"completionDate":"2023-06-30"},{"nctId":"NCT01685411","phase":"NA","title":"Busulfan and Cyclophosphamide Followed By ALLO BMT","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-01","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"enrollment":5,"completionDate":"2020-02-10"},{"nctId":"NCT04368819","phase":"PHASE2,PHASE3","title":"Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms","status":"UNKNOWN","sponsor":"Ministry of Health, Brazil","startDate":"2021-03-03","conditions":["Refractory Angina"],"enrollment":40,"completionDate":"2021-12-31"},{"nctId":"NCT03353298","phase":"PHASE2","title":"Lowering Uric Acid in Live Kidney Donors","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2018-01-17","conditions":["Renal Transplant Donor of Left Kidney","Renal Transplant Donor of Right Kidney"],"enrollment":71,"completionDate":"2020-09-25"},{"nctId":"NCT02038179","phase":"PHASE2,PHASE3","title":"Center of Research Translation (CORT) Project 2","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-07","conditions":["Pre-hypertension","JNC 7 Stage I Hypertension"],"enrollment":99,"completionDate":"2018-08"},{"nctId":"NCT02017171","phase":"PHASE3","title":"A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes","status":"COMPLETED","sponsor":"Alessandro Doria","startDate":"2014-02","conditions":["Diabetic Nephropathies","Coronary Artery Disease"],"enrollment":530,"completionDate":"2019-08-31"},{"nctId":"NCT04155918","phase":"PHASE2","title":"Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients","status":"COMPLETED","sponsor":"Arthrosi Therapeutics","startDate":"2020-02-03","conditions":["Gout Patients"],"enrollment":30,"completionDate":"2020-09-03"},{"nctId":"NCT04347005","phase":"PHASE1","title":"The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males","status":"COMPLETED","sponsor":"Arthrosi Therapeutics","startDate":"2019-01-22","conditions":["Healthy Volunteers"],"enrollment":64,"completionDate":"2019-07-31"},{"nctId":"NCT03680404","phase":"PHASE1","title":"The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction","status":"COMPLETED","sponsor":"The University of Texas at Arlington","startDate":"2018-10-01","conditions":["Cardiovascular Diseases","Cardiovascular Risk Factor","Vasoconstriction"],"enrollment":24,"completionDate":"2020-02-01"},{"nctId":"NCT02991898","phase":"PHASE2","title":"Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-02-16","conditions":["Acute Lymphoblastic Leukemia","Burkitt Lymphoma","Natural Killer Cell Malignancies","Chronic Myelogenous Leukemia","Myelodysplastic Syndromes","Large-cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Marginal Zone B-Cell Lymphoma","Follicular Lymphoma","Lymphoplasmacytic Lymphoma","Mantle-Cell Lymphoma","Prolymphocytic Leukemia","Hodgkin Lymphoma","Multiple Myeloma","Acute Myelogenous Leukemia","Biphenotypic Leukemia","Undifferentiated Leukemia"],"enrollment":3,"completionDate":"2019-06-20"},{"nctId":"NCT01637623","phase":"PHASE2","title":"Study of Cardiovascular Disease and Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2012-06","conditions":["Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour)","Hypertension"],"enrollment":87,"completionDate":"2015-06"},{"nctId":"NCT02956278","phase":"PHASE4","title":"The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-11","conditions":["Chronic Gout","Hyperuricemia"],"enrollment":27,"completionDate":"2018-03"},{"nctId":"NCT01200485","phase":"PHASE2","title":"Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-04","conditions":["Leukemia","Lymphoma"],"enrollment":55,"completionDate":"2016-07"},{"nctId":"NCT00899431","phase":"PHASE2","title":"Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-05-06","conditions":["Chronic Lymphocytic Leukemia"],"enrollment":39,"completionDate":"2018-10-07"},{"nctId":"NCT04012294","phase":"PHASE3","title":"Effects of Allopurinol on Inflammation and Ultrasonographic Changes in People With Elevated Uric Acid But no Symptoms","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2019-08-30","conditions":["Musculoskeletal Degeneration","Inflammation","Hyperuricemia"],"enrollment":200,"completionDate":"2021-02-28"},{"nctId":"NCT02790463","phase":"NA","title":"Virtual Gout Clinic","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2013-01","conditions":["Gout"],"enrollment":1463,"completionDate":"2018-10"},{"nctId":"NCT02533648","phase":"PHASE3","title":"Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2011-09-16","conditions":["Type 2 Diabetes Mellitus"],"enrollment":31,"completionDate":"2016-02-18"},{"nctId":"NCT01332799","phase":"PHASE4","title":"Xanthine Oxidase Inhibition in Renal Transplant Recipients","status":"TERMINATED","sponsor":"Roberto S Kalil","startDate":"2011-02","conditions":["Complications of Renal Transplant"],"enrollment":20,"completionDate":"2018-08-10"},{"nctId":"NCT00732251","phase":"PHASE4","title":"Allopurinol Maintenance Study for Bipolar Disorder","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2008-08","conditions":["Bipolar Disorder","Mania","Mixed Mania"],"enrollment":15,"completionDate":"2012-01"},{"nctId":"NCT02078219","phase":"PHASE2","title":"Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-01-05","conditions":["Gout and Hyperuricemia"],"enrollment":204,"completionDate":"2015-03-13"},{"nctId":"NCT02237339","phase":"PHASE4","title":"Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2014-09","conditions":["Hypertension","Hypertrophy, Left Ventricular"],"enrollment":72,"completionDate":"2017-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Injection, Tablet","formulations":[{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Allopurinol"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Allopurinol sodium"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Aloprim"},{"form":"TABLET","route":"ORAL","productName":"ALLOPURINOL"},{"form":"TABLET","route":"ORAL","productName":"Allopurinol"},{"form":"TABLET","route":"ORAL","productName":"Zyloprim"},{"form":"TABLET","route":"ORAL","productName":"Allopurinol"},{"form":"TABLET","route":"ORAL","productName":"ZYLOPRIM"},{"form":"TABLET","route":"ORAL","productName":"Zyloprim"},{"form":"TABLET","route":"ORAL","productName":"Allopurinol"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146247","MMSL":"1590","NDDF":"001084","UNII":"63CZ7GJN5I","VUID":"4017895","CHEBI":"CHEBI:40279","VANDF":"4017895","INN_ID":"1731","RXNORM":"203600","UMLSCUI":"C0002144","chemblId":"CHEMBL1467","ChEMBL_ID":"CHEMBL1467","KEGG_DRUG":"D00224","DRUGBANK_ID":"DB00437","PUBCHEM_CID":"135401907","SNOMEDCT_US":"25246002","IUPHAR_LIGAND_ID":"6795","SECONDARY_CAS_RN":"17795-21-0","MESH_DESCRIPTOR_UI":"D000493"},"formularyStatus":[],"originalProduct":{"form":"TABLET","route":"ORAL","company":"Prometheus Laboratories Inc.","brandName":"ZYLOPRIM","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1966-","companyName":"Prometheus Labs","relationship":"Original Developer"},{"period":"present","companyName":"Casper Pharma Llc","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.8 hours","clearance":"11.0 mL/min/kg","bioavailability":"53%","fractionUnbound":"0.97%","volumeOfDistribution":"0.58 L/kg"},"publicationCount":8491,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"M04AA01","allCodes":["M04AA01","M04AA51"]},"biosimilarFilings":[],"originalDeveloper":"Prometheus Labs","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":22,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Aiping Pharm Inc","Aurobindo Pharma Ltd","Chartwell","Dr Reddys","Harman Finochem","Hetero Labs Ltd V","Ipca Labs Ltd","Lupin Ltd","Mutual Pharm","Mylan","Northstar Hlthcare","Ph Health","Puracap Pharm","Purepac Pharm","Regcon Holdings","Sandoz","Sun Pharm Inds Inc","Sun Pharm Industries","Superpharm","Unichem","Zydus Pharms"],"status":"approved","companyName":"Casper Pharma Llc","companyId":"casper-pharma-llc","modality":"Small molecule","firstApprovalDate":"1966","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-07-16T00:00:00.000Z","mah":"DR REDDYS","brand_name_local":null,"application_number":"ANDA071586"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-07-16T00:00:00.000Z","mah":"DR REDDYS","brand_name_local":null,"application_number":"ANDA071587"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-12-17T00:00:00.000Z","mah":"WATSON LABS","brand_name_local":null,"application_number":"NDA018877"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-14T00:00:00.000Z","mah":"AUROBINDO PHARMA LTD","brand_name_local":null,"application_number":"ANDA215091"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-03-13T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA076870"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":11,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:22:02.974924+00:00","fieldsConflicting":14,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}